BARCELONA, Spain, November 14, 2014 /PRNewswire/ --
Veeva is the only life sciences-specific CRM provider recognised as Leader
For the second consecutive year, Veeva Systems has been named a Leader by Nucleus Research in its 2014 Technology Value Matrix for customer relationship management (CRM). Veeva is the only industry cloud player - and the only company serving life sciences - in the Leader quadrant, which represents the top tier of CRM providers.
(Logo: http://photos.prnewswire.com/prnh/20120425/527164 )
Nucleus Research considers candidates' track record of innovation in system functionality and usability, particularly in the areas of sales, marketing, and customer service. The 2014 release of Veeva Commercial Cloud, which brings together the data, content, and interactions needed for life sciences companies to deliver a fully coordinated and compliant customer experience, helped push Veeva over the top as a premier cloud provider. Nucleus Research expects the company to further strengthen its position in the leadership matrix as it expands Veeva Commercial Cloud with new offerings.
"As a trusted partner to the global life sciences industry, we constantly strive to innovate and deliver cloud-based solutions that enable our customers to achieve their most strategic objectives," said Paul Shawah, vice president of product marketing for Veeva. "We're honoured to be named a CRM industry leader for the second year in a row. This further attests to our continued commitment to bring industry cloud solutions that help life sciences organisations get drugs to market faster and maximise sales, while maintaining regulatory compliance."
A set of unified applications built for life sciences, Veeva Commercial Cloud marries Veeva CRM, Veeva Network customer master, and Veeva Vault for regulated content management. With key applications for their most strategic business areas interoperating seamlessly in the cloud, companies can deliver a fully orchestrated, personalised, and compliant customer experience.
The recognition from Nucleus Research follows a host of recent industry awards, including the Deloitte Fast 500, the American Business Awards, Network Product's Guide Hot Companies, and PM360 innovative products list, also announced today. Read the full announcement.
Additional Information
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 200 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva
is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit http://www.veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including statements regarding benefits from the use of Veeva's solutions, demand for Veeva's solutions, and general business conditions. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended July 31, 2014, which is available on the company's website at http://www.veeva.com under the Investors section and on the SEC's website at http://www.sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
Share this article